A study of blood and tumor samples to learn why glioblastoma comes back
Official title: A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
Doctors are studying samples from people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary to learn what makes the tumor grow back.
Read our full plain-language summary
What the trial team says
BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.
Key facts
- Registry number
- NCT07173829
- Conditions studied
- Glioblastoma
Where it is running
This trial lists 1 site.
-
France
- CHU de Bordeaux (Bordeaux)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.